2018 Korean Clinical Imaging Guideline for Hemoptysis.
10.3348/kjr.2018.19.5.866
- Author:
Mi Jin KANG
1
;
Jin Hwan KIM
;
Yoon Kyung KIM
;
Hyun Joo LEE
;
Kyung Min SHIN
;
Jung Im KIM
;
Hyun Ju LEE
;
Kyung Hyun DO
;
Hwan Seok YONG
;
Sol Ji CHOI
;
Miyoung CHOI
;
Jung Im JUNG
Author Information
1. Department of Radiolgoy, InJe University Sanggye Paik Hospital, Seoul 01757, Korea.
- Publication Type:Review
- Keywords:
Guideline;
Hemoptysis;
Thorax;
Lung;
Radiography;
X-ray;
Computed tomography;
Evidence;
Republic of Korea
- MeSH:
Adult;
Advisory Committees;
Consensus;
Hemoptysis*;
Humans;
Korea;
Lung;
Lung Neoplasms;
Pulmonary Fibrosis;
Radiography;
Republic of Korea;
Risk Factors;
Smoke;
Smoking;
Thorax;
Tomography, X-Ray Computed;
Tuberculosis
- From:Korean Journal of Radiology
2018;19(5):866-871
- CountryRepublic of Korea
- Language:English
-
Abstract:
In 2014, the American College of Radiology (ACR) announced the guideline for the appropriate diagnostic approach and treatment of patients according to the severity of hemoptysis and risk for lung cancer. However, the application of the ACR guideline in Korea may not be appropriate, because many patients in Korea have active tuberculosis or pulmonary fibrosis due to previous tuberculosis. The Korean Society of Radiology and Korean Society of Thoracic Radiology have proposed a new guideline suitable for Korean practice. This new guideline was prepared through the consensus of a development committee, working party, and an advisory committee. The guideline proposal process was based on an evidence-based clinical imaging guideline proposed by the development committee. Clinical imaging guideline for adult patients with hemoptysis is as follows: Chest radiography is an initial imaging modality to evaluate hemoptysis. Contrast-enhanced chest CT is recommended in patients with two risk factors for lung cancer (> 40 years old and > 30 pack-year smoking history), moderate hemoptysis (> 30 mL/24 hours) or recurrent hemoptysis. Contrast-enhanced chest CT is also recommended in patients with massive hemoptysis (> 400 mL/24 hours) without cardiopulmonary compromise.
